The phase IIa placebo-controlled study evaluated the efficacy and safety of Tetrodin (tetrodotoxin) in reducing withdrawal symptoms in 14 methadone-maintained participants. Researchers used the opioid antagonist naloxone to
This gives Anadys the go-ahead to evaluate its lead compound ANA975 in the US. Under the companies joint development and commercialization collaboration created earlier this year, Novartis will
The open label clinical trial met its primary objective of maintaining the bone mineral density (BMD) of women with systemic lupus erythematosus (SLE or lupus) receiving glucocorticoids. The
The randomized, placebo-controlled study is part of a broad clinical development program to evaluate the anti-inflammatory effects of MLN1202, a novel humanized monoclonal antibody, in a number of
Singulair (montelukast sodium) is now approved to be used to treat asthma, seasonal allergies and perennial allergic rhinitis (PAR). The medication can be taken by adults and children
The novel mTOR inhibitor, AP23573, is designed to fight cancers of the connective tissues including bones, muscles, fat, cartilage, and joints. These sarcomas usually belong to one of
Under the terms of the agreement, Dyax receives an upfront technology license fee from Merck, as well as annual maintenance fees, clinical milestone payments and royalties on net
Genmab will receive a license fee of $20 million, and Serono will make a $50 million investment in Genmab common stock. If all milestone targets are reached, Genmab
Results of the trial demonstrated that 300mg of darusentan dosed once daily provided statistically significant, placebo-corrected reductions in systolic blood pressure and diastolic blood pressure. Clinically meaningful reductions
The sale, which is expected to give Boots GBP1.2 billion ($2.17 billion), has attracted many players in the industry, including German drugs group Bayer, US firm Pfizer and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.